What we promise?
Product | Atorvastatin Cyclic (Fluorophenyl) Sodium |
---|---|
CAT No. | CS-O-15160 |
CAS No. | 1315629-79-8 |
Status | Available for Dispatch by 24-Sep-2023 |
Category | Impurities |
Mol. Wt. | 612.62 g/mol mol/g |
Mol. For. | C₃₃H₃₄FN₂NaO₇ |
Hazardous |
![]() |
Atorvastatin Cyclic (Fluorophenyl) Sodium is a medication used to treat high cholesterol levels and prevent cardiovascular diseases. It belongs to the class of drugs known as statins, which work by inhibiting the production of cholesterol in the liver. Atorvastatin Cyclic (Fluorophenyl) Sodium is a more potent form of Atorvastatin, with an added cyclic fluorophenyl group, which enhances its therapeutic effects. Chemically, Atorvastatin Cyclic (Fluorophenyl) Sodium is a sodium salt of Atorvastatin, with a molecular formula of C33H34F2NaO5S. It is a white, crystalline powder that is soluble in water and ethanol. Atorvastatin Cyclic (Fluorophenyl) Sodium is typically administered orally in tablet form, with dosages ranging from 10mg to 80mg, depending on the severity of the patient's condition. As with any medication, Atorvastatin Cyclic (Fluorophenyl) Sodium has potential side effects, such as muscle pain, liver damage, and digestive problems. Patients should consult with their healthcare provider before taking Atorvastatin Cyclic (Fluorophenyl) Sodium, especially if they have a history of liver or kidney disease, or are taking any other medications. Overall, Atorvastatin Cyclic (Fluorophenyl) Sodium is an effective medication for regulating cholesterol levels and reducing the risk of cardiovascular diseases. Its chemical properties and therapeutic effects make it a valuable tool in the fight against high cholesterol and heart disease.
Packing | Product will be supplied in Vials, in certain conditions we also use 'Septa Vials' |
---|---|
Controlled | No |
Parent API | Atorvastatin |
Therapeutic | Anti-Diabetic |
Smileys | CC(C)C1(C2(C(O2)(C3(N1CCC(O3)CC(CC(=O)[O-])O)C4=CC=C(C=C4)F)C5=CC=CC=C5)C(=O)NC6=CC=CC=C6)O.[Na+] |
Canonical Smiles | CC(C)C1(C2(C(O2)(C3(N1CCC(O3)CC(CC(=O)[O-])O)C4=CC=C(C=C4)F)C5=CC=CC=C5)C(=O)NC6=CC=CC=C6)O.[Na+] |
InchIKey | SJDGRTRCGRODGR-UHFFFAOYSA-M |
Inchl | InChI=1S/C33H35FN2O7.Na/c1-21(2)32(41)31(29(40)35-25-11-7-4-8-12-25)30(43-31,22-9-5-3-6-10-22)33(23-13-15-24(34)16-14-23)36(32)18-17-27(42-33)19-26(37)20-28(38)39;/h3-16,21,26-27,37,41H,17-20H2,1-2H3,(H,35,40)(H,38,39);/q;+1/p-1 |
IUPAC | sodium;4-[1-(4-fluorophenyl)-5-hydroxy-2-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-3,10-dioxa-6-azatricyclo[4.4.0.02,4]decan-9-yl]-3-hydroxybutanoate |
Hazardous | Yes |
General Information | Use proper personal protective equipment |
---|---|
Handling | Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation. |
Engineering Control | Use adequate general or local exhaust ventilation to keep airborne concentrations below the permissible exposure limits. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels. |
Clothing | Wear appropriate protective clothing to minimize contact with skin. |
Skin | Wear appropriate protective gloves and clothing to prevent skin exposure. |
Eyes | Wear safety glasses and chemical goggles if splashing is possible. |
Inhalation | Remove from exposure and move to fresh air immediately. |
![]() |
Atorvastatin Cyclic ... | www.clearsynth.com |
CAT : CS-O-15160 | BATCH : CSC-WWW0757 |
|
MF: C₃₃H₃₄FN₂NaO₇ CAS: 1315629-79-8 Date of Anaysis: 19-Aug-2023 Retest Date: 19-Jun-2026 |
MW: 612.62 g/mol
Store at refrigerator (2-8C) |
Qty: 60 MG |
Only for R & D and Analytical purpose, Not for Human Consumption. |
Impurities
Impurities
API Standards
API Standards
Impurities
Impurities
Impurities
Impurities
Intermediates
Metabolites
Impurities
Impurities
Impurities
Glucuronides
Impurities
Impurities
API Standards
API Standards
EP Standards
Secondary Standards
Impurities
Impurities
Stable Isotopes
Stable Isotopes
Stable Isotopes
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Impurities
Need a Quote?
Your email address will not be published. Required fields are marked *